Arrowhead CEO Anzalone Sells 85,000 Shares for $5.44 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Source: NASDAQ.COM
- Insider Sale: Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 85,000 shares on December 17, 2025, for approximately $5.44 million, reducing his direct holdings to 3,831,957 shares, which reflects his ongoing tax planning strategy.
- Market Reaction: This stock sale occurred against the backdrop of Arrowhead's share price surge following FDA approval of its first drug, Redemplo, which reached a 52-week high of $76.76 on January 6, 2026, indicating strong market optimism about the company's prospects.
- Holding Value: Post-transaction, Anzalone's remaining shares are valued at $248,310,813.60, underscoring his significant financial stake in the company, although the sale may raise some market concerns.
- Strategic Implications: The sale did not trigger panic in the market but was viewed as a prudent tax planning move, demonstrating executive confidence in the company's future while highlighting Arrowhead's competitive edge in RNA interference technology.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 75.50 USD with a low forecast of 35.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 65.580
Low
35.00
Averages
75.50
High
100.00
Current: 65.580
Low
35.00
Averages
75.50
High
100.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arrowhead Pharmaceuticals to Host Q1 2026 Financial Results Call on February 5, 2026
- Earnings Call Announcement: Arrowhead Pharmaceuticals will host a conference call on February 5, 2026, at 4:30 PM ET to discuss its Q1 2026 financial results, aiming to provide investors with insights into its financial performance and future outlook.
- Webcast Access: Investors can access a live audio webcast on the Events and Presentations page of Arrowhead's website, with a replay available approximately two hours after the call, ensuring that those unable to attend live can still receive key information.
- Analyst Registration: Analysts wishing to participate in the call must register in advance, receiving a dial-in number and personalized PIN code, a process designed to ensure orderly participation and enhance engagement during the call.
- Company Overview: Arrowhead Pharmaceuticals focuses on developing medicines that treat intractable diseases through gene silencing technology, leveraging RNA interference mechanisms to achieve rapid, deep, and durable knockdown of target genes, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
Continue Reading
Sanofi Secures Approval for Two Innovative Drugs Targeting Heart Disease and High Triglycerides
- Drug Approvals: Sanofi's Myqorzo (aficamten) and Redemplo (plozasiran) have received approval from China's National Medical Products Administration, with Myqorzo targeting obstructive hypertrophic cardiomyopathy and Redemplo aimed at lowering triglyceride levels in patients with familial chylomicronaemia syndrome, marking a significant advancement in the cardiovascular space.
- Myqorzo Mechanism: Myqorzo is a selective small-molecule cardiac myosin inhibitor designed to improve functional capacity and relieve symptoms in patients with obstructive hypertrophic cardiomyopathy, which is the most common monogenic inherited cardiovascular disorder, and is expected to significantly enhance patient quality of life.
- Redemplo Mechanism: Redemplo is a small-interfering RNA (siRNA) medicine that suppresses the production of apoc-III to lower triglyceride levels in patients with familial chylomicronaemia syndrome, helping to reduce the risk of severe complications like acute pancreatitis, highlighting its clinical significance.
- Market Outlook: Sanofi acquired the rights to develop and commercialize Redemplo in Greater China in 2025, demonstrating the company's commitment to the region and is expected to further strengthen its market position in the cardiovascular sector with the launch of these two innovative drugs.
Continue Reading